ScinoPharm Kunshan(SPK) was established in 2001 as a move by ScinoPharm Taiwan into China . We currently have about 120 employees devoted
to Process Development, Analytical Research
and Development, and small scale production. We
expect to continually expand our activities in China and the
development of our staff will follow this goal.
Our Kunshan operation is focused on process R&D of API and API intermediates, scale-up
of API intermediates, and non-GMP production of key intermediates for our
parent company, ScinoPharm Taiwan. This is conducted either to support
our parent company's generic/brand API manufacturing business or for the pre-GMP portion of CRO projects. |
|
|